NCT05486637 Vocal Emotion Communication With Cochlear Implants
| NCT ID | NCT05486637 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | Father Flanagan's Boys' Home |
| Condition | Cochlear Hearing Loss |
| Study Type | INTERVENTIONAL |
| Enrollment | 255 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 255 participants in total. It began in 2022-07-01 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Patients with hearing loss who use cochlear implants (CIs) show significant deficits and strong unexplained intersubject variability in their perception and production of spoken emotions in speech. This project will investigate the hypothesis that "cue-weighting", or how patients utilize the different acoustic cues to emotion, accounts for significant variance in emotional communication with CIs. The results will focus on children with CIs, but parallel measures in postlingually deaf adults with CIs will be made, ensuring that results of these studies benefit social communication by CI patients across the lifespan by informing the development of technological innovations and improved clinical protocols.
Eligibility Criteria
Inclusion Criteria: * Prelingually deaf children with cochlear implants * Postlingually deaf adults with cochlear implants * Normally hearing children * Normally hearing adults Exclusion Criteria: * Non-native speakers of American English * Prelingually deaf individuals who receive cochlear implants after age 12 * Adults unable to pass a basic cognitive screen
Contact & Investigator
Monita Chatterjee, Ph.D.
PRINCIPAL INVESTIGATOR
Father Flanagan's Boys' Home
Frequently Asked Questions
Who can join the NCT05486637 clinical trial?
This trial is open to participants of all sexes, aged 6 Years or older, up to 80 Years, studying Cochlear Hearing Loss. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT05486637 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT05486637 currently recruiting?
Yes, NCT05486637 is actively recruiting participants. Contact the research team at monita.chatterjee@northwestern.edu for enrollment information.
Where is the NCT05486637 trial being conducted?
This trial is being conducted at Tempe, United States, Los Angeles, United States, Evanston, United States, Omaha, United States.
Who is sponsoring the NCT05486637 clinical trial?
NCT05486637 is sponsored by Father Flanagan's Boys' Home. The principal investigator is Monita Chatterjee, Ph.D. at Father Flanagan's Boys' Home. The trial plans to enroll 255 participants.